{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:35:42Z","timestamp":1783654542043,"version":"3.55.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.therap.2024.10.054","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:24:50Z","timestamp":1729643090000},"page":"177-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Monitoring misuse and abuse of psychoactive substances in France: Insights from substance abuse treatment facilities through the OPPIDUM program"],"prefix":"10.1016","volume":"80","author":[{"given":"Cl\u00e9mence","family":"Lacroix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Frauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Jouve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2024.10.054_bib0245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neuropharm.2014.04.014","article-title":"Human abuse liability evaluation of CNS stimulant drugs","volume":"87","author":"Romach","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.therap.2024.10.054_bib0250","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.drugalcdep.2009.04.003","article-title":"Principles of laboratory assessment of drug abuse liability and implications for clinical development","volume":"105","author":"Carter","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.054_bib0255","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0376-8716(03)00098-X","article-title":"Principles of initial experimental drug abuse liability assessment in humans","volume":"70","author":"Griffiths","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.054_bib0260","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2515\/therapie\/2015011","article-title":"Signal Identification in addictovigilance: the functioning of the French system","volume":"70","author":"Jouanjus","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0265","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.therap.2019.09.005","article-title":"D\u00e9tection des signaux du r\u00e9seau fran\u00e7ais d\u2019addictovigilance\u00a0: m\u00e9thodes innovantes d\u2019investigation, illustrations et utilit\u00e9 pour la sant\u00e9 publique","volume":"74","author":"Micallef","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0270","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/fcp.12024","article-title":"OPPIDUM surveillance program: 20 years of information on drug abuse in France","volume":"27","author":"Frauger","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0275","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.encep.2009.03.011","article-title":"\u00c9valuation des conduites addictives chez les personnes entrant en milieu p\u00e9nitentiaire \u00e0 partir du programme OPPIDUM du r\u00e9seau des centres d\u2019\u00e9valuation et d\u2019information sur la pharmacod\u00e9pendance (CEIP)","volume":"36","author":"Pauly","year":"2010","journal-title":"Encephale"},{"key":"10.1016\/j.therap.2024.10.054_bib0280","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/fcp.12738","article-title":"Antidepressants abuse in subjects with opioid use disorders: a 10-year study in the French OPPIDUM program","volume":"36","author":"Dumonceau","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/fcp.12233","article-title":"Which psychoactive substances are used by patients seen in the healthcare system in French overseas territories? Results of the OPPIDUM survey","volume":"31","author":"Daveluy","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0290","first-page":"586","article-title":"Observation of illicit or misused psychotropic drugs (O.P.P.I.D.U.M.): five years of surveillance of products consumed by drug addicts at Marseille","volume":"51","author":"San Marco","year":"1996","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0295","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000050711","article-title":"Observation of psychoactive substance consumption: methods and results of the French OPPIDUM programme","volume":"7","author":"Thirion","year":"2001","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.10.054_bib0300","unstructured":"Drug Abuse Warning Network (DAWN)\u00a0\u2013\u00a0SAMHSA. 2022. https:\/\/www.samhsa.gov\/data\/release\/2022-drug-abuse-warning-network-dawn-releases. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0305","first-page":"128","article-title":"Le programme OPPIDUM\u202f: d\u00e9j\u00e0 20 ans d\u2019exp\u00e9rience\u202f!","volume":"23","author":"Frauger","year":"2009","journal-title":"Lett Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0310","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2515\/therapie\/2012064","article-title":"Les CAARUD, lieux privil\u00e9gi\u00e9s d\u2019\u00e9mergence de signaux pour l\u2019addictovigilance","volume":"67","author":"Moracchini","year":"2012","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0315","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.therap.2017.01.010","article-title":"Dispositif pharmaco\u00e9pid\u00e9miologique de surveillance des substances psychoactives\u00a0: int\u00e9r\u00eats du programme national OPPIDUM du R\u00e9seau fran\u00e7ais d\u2019addictovigilance","volume":"72","author":"Frauger","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0320","unstructured":"ANSM. R\u00e9sultats d\u2019enqu\u00eates pharmacod\u00e9pendance-addictovigilance. 2021. https:\/\/ansm.sante.fr\/page\/resultats-denquetes-pharmacodependance-addictovigilance. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0325","unstructured":"Observation des produits psychotropes illicites ou d\u00e9tourn\u00e9s de leur utilisation m\u00e9dicamenteuse 2024. https:\/\/addictovigilance.fr\/programmes-dobservation\/oppidum\/. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0330","series-title":"Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM IV-TR)","year":"2013"},{"key":"10.1016\/j.therap.2024.10.054_bib0335","unstructured":"Legifrance. Code de la Sant\u00e9 publique, article R. 5132-97. 2019. https:\/\/www.legifrance.gouv.fr\/codes\/article_lc\/LEGIARTI000039659171. [Accessed 9 July 2024]"},{"key":"10.1016\/j.therap.2024.10.054_bib0340","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/fcp.12346","article-title":"Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France","volume":"32","author":"Pochard","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0345","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.therap.2022.10.003","article-title":"Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: insights of the annual cross-sectional OPPIDUM survey","volume":"78","author":"Blayac","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/pds.2263","article-title":"Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey","volume":"21","author":"Nordmann","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.therap.2024.10.054_bib0355","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2515\/therapie:2008037","volume":"63","author":"Frauger","year":"2008","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0360","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1472-8206.2011.00950.x","article-title":"Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey","volume":"26","author":"Frauger","year":"2012","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0365","first-page":"243","article-title":"Dependence on psychotropic drugs and substitution treatment: recent trends. The OPPIDUM study of the Centers for Evaluation and Information on Drug Dependence (CEIP), October 1997","volume":"54","author":"Thirion","year":"1999","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0370","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.therap.2023.02.002","article-title":"Alprazolam misuse: analysis of French Addictovigilance Network data from 2011 to 2020","volume":"78","author":"Diaz","year":"2023","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0375","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/fcp.12210","article-title":"Evidence of slow-release morphine sulfate abuse and diversion: epidemiological approaches in a French administrative area","volume":"30","author":"Peyriere","year":"2016","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0380","unstructured":"ANSM. Rohypnol (flunitraz\u00e9pam) 1 mg \u2013 Arr\u00eat de commercialisation \u2013 Point d\u2019information. 2013. https:\/\/archive.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Rohypnol-flunitrazepam-1-mg-Arret-de-commercialisation-Point-d-information. [Accessed 9 July 2024]"},{"key":"10.1016\/j.therap.2024.10.054_bib0385","unstructured":"ANSM. Rivotril\u00ae (clonaz\u00e9pam) : modification des conditions de prescription et de d\u00e9livrance \u2013 Point d\u2019information. 2011. https:\/\/archive.ansm.sante.fr\/S-informer\/Points-d-information-Points-d-information\/Rivotril-R-clonazepam-Modification-des-conditions-de-prescription-et-de-delivrance-Point-d-information. [Accessed 9 July 2024]"},{"key":"10.1016\/j.therap.2024.10.054_bib0390","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/YIC.0b013e32834967e5","article-title":"Monitoring of benzodiazepine diversion using a multi-indicator approach","volume":"26","author":"Pauly","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2012.03.009","article-title":"Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France","volume":"126","author":"Pauly","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.therap.2024.10.054_bib0400","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2515\/therapie:2006014","article-title":"D\u00e9tournement d\u2019usage du clonaz\u00e9pam (Rivotril\u00ae)\u00a0: tendances r\u00e9centes","volume":"61","author":"Frauger","year":"2006","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0405","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1472-8206.2010.00882.x","article-title":"Evidence of clonazepam abuse liability: results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network","volume":"25","author":"Frauger","year":"2011","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0410","unstructured":"EMCDDA. Annual report on the state of the drugs problem in Europe. 2010. https:\/\/www.emcdda.europa.eu\/publications\/annual-report\/2010_en. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0415","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","article-title":"Pregabalin abuse and dependence in Germany: results from a database query","volume":"69","author":"Gahr","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0420","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/JCP.0b013e318272864d","article-title":"Pregabalin misuse\u2013related issues; intake of large dosages, drug-smoking allegations, and possible association with myositis: two case reports","volume":"32","author":"Carrus","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0425","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s40263-024-01095-y","article-title":"Patterns of pregabalin users from substance abuse treatment facilities: results from the French OPPIDUM program from 2008 to 2022","volume":"38","author":"Garnier","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.therap.2024.10.054_bib0430","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2515\/therapie\/2015014","article-title":"Evaluation of abuse and dependence in addiction monitoring systems: tramadol as an example","volume":"70","author":"Roussin","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2024.10.054_bib0435","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1111\/bcp.15323","article-title":"Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: evidence from the triangulation of addictovigilance data","volume":"88","author":"Roussin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0440","doi-asserted-by":"crossref","unstructured":"ANSM. Tramadol : moins de comprim\u00e9s dans les bo\u00eetes pour un meilleur usage. 2024. https:\/\/ansm.sante.fr\/actualites\/tramadol-moins-de-comprimes-dans-les-boites-pour-un-meilleur-usage_Diminuer_le_nombre_de_comprime_a_risques_pour_les_proches. [Accessed 9 July 2024].","DOI":"10.1016\/S1773-035X(24)00243-0"},{"key":"10.1016\/j.therap.2024.10.054_bib0445","unstructured":"ANSM. Tramadol : une mesure pour limiter le m\u00e9susage en France. 2020. https:\/\/ansm.sante.fr\/actualites\/tramadol-une-mesure-pour-limiter-le-mesusage-en-france. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0450","unstructured":"SAMHSA. Treatment episode data set (TEDS). 2024. https:\/\/www.samhsa.gov\/data\/data-we-collect\/teds-treatment-episode-data-set. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0455","unstructured":"SAMRC. South African Community Epidemiology Network on Drug Use (SACENDU). 2024. https:\/\/www.samrc.ac.za\/intramural-research-units\/MASTRU-sacendu. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0460","unstructured":"EMCDDA. European Drug Emergencies Network (Euro-DEN Plus): data and analysis. 2024. https:\/\/www.emcdda.europa.eu\/publications\/data-factsheet\/european-drug-emergencies-network-euro-den-plus-data-and-analysis_en#section0. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0465","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000439273","article-title":"Patterns of methylphenidate use and assessment of its abuse among the general population and individuals with drug dependence","volume":"22","author":"Frauger","year":"2016","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.therap.2024.10.054_bib0470","unstructured":"ANSM. D\u00e9cision du 12\/06\/2023 portant modification de la liste des substances class\u00e9es comme stup\u00e9fiants. 2023. https:\/\/ansm.sante.fr\/actualites\/decision-du-12-06-2023-portant-modification-de-la-liste-des-substances-classees-comme-stupefiants. [Accessed 9 July 2024]."},{"key":"10.1016\/j.therap.2024.10.054_bib0475","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/fcp.12603","article-title":"Health consequences of cocaine use in France: data from the French Addictovigilance Network","volume":"35","author":"Eiden","year":"2021","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.therap.2024.10.054_bib0480","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/eurpub\/ckad003","article-title":"French national addictovigilance follow-up of zolpidem between 2014 and 2020: evolution of drug abuse, misuse and dependence before and after the regulatory change","volume":"33","author":"Aquizerate","year":"2023","journal-title":"Eur J Public Health"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595724001707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T12:34:17Z","timestamp":1744202057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595724001707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S0040595724001707"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.054","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring misuse and abuse of psychoactive substances in France: Insights from substance abuse treatment facilities through the OPPIDUM program","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2024.10.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}